Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 117-125

  Arnt, J ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Hypermotility; Limbic dopamine; Rats; Reward

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMPEROZIDE; CLOZAPINE; DEXAMPHETAMINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; LYSERGIDE; MEPYRAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PRAZOSIN; QUETIAPINE; QUIPAZINE; REMOXIPRIDE; RISPERIDONE; RITANSERIN; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SERTINDOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANHEDONIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG DISCRIMINATION; DYSPHORIA; ETIOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC SYSTEM; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; SUBCUTANEOUS DRUG ADMINISTRATION;

AMPHETAMINE; AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; RATS; RATS, WISTAR; REWARD;

EID: 0030012215     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245611     Document Type: Article

References (42)

1. 2 dopamine antagonist: an examination of its self-administration liability and its effects on D-amphetamine self-administration. Pharmacol Biochem Behav 41:259-261
2. Arnt J (1992) Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine. LSD and St 587 in rats. Behav Pharmacol 3:11-18
3. Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by 2 dose levels of D-amphetamine. Eur J Pharmacol 283:55-62
4. Arnt J, Sánchez C, Skarsfeldt T (1994) The so-called atypical antipsychotics - how similar are they? Neuropsychopharmacology 10:469S
5. Bozarth MA (1991) The mesolimbic dopamine system as a model reward system. In: Willner P, Scheel-Krüger J (eds) The mesolimbic dopamine system: from motivation to action. Wiley, New York
6. Chiodo LA, Bunney BS (1985) Possible mechanisms by which repealed clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539-2544
7. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenler placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
8. Costall B, Fortune DH, Hui S-CG, Naylor RJ (1980) Neuroleptic antagonism of the motor inhibitory effects of apomorphine within the nucleus accumbens: drug interaction at presynaptic receptors? Eur J Pharmacol 63:347-358
9. Glennon RA (1986) Discriminative stimulus properties of the serotonergic agent 1-(2,5-di-methoxy-4-iodophenyl)-2-amino-propane (DOI). Life Sci 39:825-830
10. Hall H, Sällemark M, Jerning E (1986) Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Acta Pharmacol Toxicol 58:61-70
11. Harrison DA, Satterlee W, Tran P, Beasley CM, Tollefson GD (1994) Olanzapine: a potential "atypical" antipsychotic agent - phase II clinical findings. Schizophr Res 11:107
12. Heishman SJ, Henningfield JE (1991) Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazapam in humans. Psychopharmacology 103:436-442
13. Hyttel J, Nielsen JB, Nowak G (1992) The acute effect of sertin-dole on brain neurotransmitter receptors (ex vivo radio-receptor studies). J Neural Transm 89:61-69
14. Inglis WL, Dunhar JS, Winn P (1994) Outflow from the nucleus accumbens to the pedunculopontine tegmental nucleus: a dissociation between locomotor activity and the acquisition of responding for conditioned reinforcement stimulated by d-amphetamine. Neuroscience 62:51-64
15. Kelly PH, Seviour PW, Iversen SD (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94:507-522
16. Lewander T (1994) Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 89:8-13
17. Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5-HT2 receptors. Psychopharmacology 112:S40-S54
18. Leysen JE, Schotte A, Janssen PMF, Gommeren W, Van Gompel P, Lesage AS, De Backer MD, Luyten WHML, Amlaiky N, Megens AAHP (1995) Interaction of new antipsychotics with neurotransmitter receptors in vitro and in vivo: pharmacological to therapeutic significance. In: Fog R, Gerlach J, Hemmingsen R (eds) Schizophrenia. Alfred Benzon Symposium 38, Munksgaard, Copenhagen, pp 344-356
19. Mack R, Zborowski J, Morris D, Sebree T, Wallin B (1995) Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients. Proceedings ACNP Meeting (in press)
20. 3 receptors. Mol Pharmacol 43:749-754
21. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265:498-508
22. Meert TF, De Haes PLAJ, Vermote PCM, Janssen PAJ (1990) Pharmacological validation of ritanserin and risperidone in the drug discrimination test procedure in the rat. Drug Dev Res 19:353-373
23. Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604
24. Meltzer HY, Bastani B, Young Kwon K, Ramirez LF, Burnett S, Sharpe J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 99:68-72
25. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
26. Muscat R, Kyprianou T, Osman M, Philips G, Willner P (1991) Sweetness-dependent facilitation of sucrose drinking by raclopride is unrelated to calorie content. Pharmacol Biochem Behav 40:209-213
27. Nielsen EB, Jepsen SA (1985) Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur J Pharmacol 111:167-176
28. Nielsen EB, Scheel-Krüger J (1986) Cueing effects of amphetamine and LSD: elicitation by direct microinjections of the drugs into the nucleus accumbens. Eur J Pharmacol 125:85-92
29. 2 receptors. Neuroscience 61:269-283
30. Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembøl HL, Meier E, Skarsfeldt T (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239-250
31. Schreiber R, Brocco M, Millan MJ (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100907 and the "atypical" antipsychotics, clozapine and risperidone. Eur J Pharmacol 264:99-102
32. Seeman P, Van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270
33. Skarsfeldt T (1988) Differential effects after repeated treatment with haloperidol, clozapine, thoridazine and tefludazine on SNC and VTA dopamine neurones in rats. Life Sci 42: 1037-1044
34. Skarsfeldt T (1992) Electrophysiological profile of a new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10:25-33
35. Skarsfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281:289-294
36. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691
37. 2 receptors. J Pharmacol Exp Ther 266:1374-1384
38. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB, Sertindole Study Group (1986) A randomized, controlled, doseranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124:168-175
39. Wålinder J, Holm A-C (1990) Experiences of long-term treatment with remoxipride: efficacy and tolerability. Acta Psychiatr Scand 82:158-163
40. Willner P (1991) Animal models as simulation of depression. Trends Neurosci 12:131-136
41. Wise RA (1982) Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 5:39-87
42. Wise RA, Rompre P-P (1989) Brain dopamine and reward. Annu Rev Psychol 40:191-225